Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Up – What’s Next?

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) shares gapped up prior to trading on Thursday. The stock had previously closed at $8.77, but opened at $9.53. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $9.10, with a volume of 1,562 shares changing hands.

Analyst Upgrades and Downgrades

Separately, Jefferies Financial Group upgraded Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 14th. Two investment analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy”.

Shionogi & Co., Ltd. Unsponsored ADR Price Performance

The company has a market cap of $15.69 billion, a P/E ratio of 9.22, a P/E/G ratio of 3.27 and a beta of 0.08. The company’s 50-day moving average price is $9.07 and its two-hundred day moving average price is $9.27. The company has a current ratio of 1.14, a quick ratio of 1.00 and a debt-to-equity ratio of 0.01.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last issued its quarterly earnings results on Monday, August 3rd. The company reported $0.36 EPS for the quarter, topping the consensus estimate of $0.18 by $0.18. The business had revenue of $1.04 billion for the quarter, compared to analysts’ expectations of $970.69 million. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 46.67% and a return on equity of 16.13%. As a group, sell-side analysts expect that Shionogi & Co., Ltd. Unsponsored ADR will post 0.82 earnings per share for the current year.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. is a Japan-based research-driven pharmaceutical company headquartered in Osaka. Founded in 1878, the company discovers, develops, manufactures and markets prescription medicines, with a focus on infectious diseases, central nervous system disorders and other areas of unmet medical need.

Shionogi’s portfolio includes Xofluza (baloxavir marboxil), an antiviral treatment for influenza, and F. (fostemsavir), an HIV treatment marketed in certain regions. The company also develops medicines for conditions including pain, psychiatric disorders and other diseases, while pursuing research in areas such as antimicrobial resistance and novel anti-infective therapies.

Shionogi primarily serves the Japanese market and has expanded its international presence through subsidiaries, licensing arrangements and commercial partnerships in North America, Europe and other regions.